Evaluation of SYX-5219 on Immune Response Modulation in Patients with Atopic Dermatitis

The trial enrolled healthy volunteers of both sexes; however, the sponsor did not provide the total number of participants. The specific age range of the cohort was not disclosed. Participants were selected on the basis of being free of clinical disease, including the condition under investigation, Atopic dermatitis (AD). No detailed information regarding lifestyle factors such as diet, physical activity, or other habits was provided, and the inclusion and exclusion criteria beyond general health status were not specified.

The study is a phase 3, randomized, double‑blind, placebo‑controlled trial evaluating the effect of SYX‑5219 on the immune response in the skin of participants with atopic dermatitis. Recruitment is planned to begin on 22 October 2025 and to conclude by 14 February 2026. After informed consent, a screening visit confirms eligibility, followed by a baseline visit in which participants are randomized to active or placebo arms. Subsequent study visits are scheduled at predetermined intervals throughout the treatment period to assess safety, pharmacodynamics, and clinical outcomes, culminating in an end‑of‑study visit after the final dose. Participant involvement spans the entire study duration, from screening through the end‑of‑study assessment. Early discontinuation may occur if a participant experiences a serious adverse event, violates protocol requirements, or withdraws consent.

Efficacy assessments in this phase 3 study involving participants with atopic dermatitis will be performed according to the predefined protocol schedule, with relevant clinical data collected at specified study visits throughout the treatment period.